109 related articles for article (PubMed ID: 37632035)
1. Virus Inactivation by Formaldehyde and Common Lysis Buffers.
Seeburg U; Urda L; Otte F; Lett MJ; Caimi S; Mittelholzer C; Klimkait T
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632035
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives.
Welch SR; Davies KA; Buczkowski H; Hettiarachchi N; Green N; Arnold U; Jones M; Hannah MJ; Evans R; Burton C; Burton JE; Guiver M; Cane PA; Woodford N; Bruce CB; Roberts ADG; Killip MJ
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32839250
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 inactivation in laboratory animal tissues with 4% formaldehyde or 5% glutaraldehyde for transfer to biosafety level 1 laboratories.
Pilchová V; Elmontaser Mergani A; Clever S; Ciurkiewicz M; Becker K; Gerhauser I; Baumgärtner W; Volz A; von Köckritz-Blickwede M; Schulz C
Vet Pathol; 2024 Mar; 61(2):201-206. PubMed ID: 37698272
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms.
Thom RE; Eastaugh LS; O'Brien LM; Ulaeto DO; Findlay JS; Smither SJ; Phelps AL; Stapleton HL; Hamblin KA; Weller SA
Front Cell Infect Microbiol; 2021; 11():716436. PubMed ID: 34604108
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings.
Widera M; Westhaus S; Rabenau HF; Hoehl S; Bojkova D; Cinatl J; Ciesek S
Med Microbiol Immunol; 2021 Aug; 210(4):235-244. PubMed ID: 34196781
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples.
Pastorino B; Touret F; Gilles M; Luciani L; de Lamballerie X; Charrel RN
Viruses; 2020 Jun; 12(6):. PubMed ID: 32521706
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of virus inactivation by formaldehyde to enhance biosafety of diagnostic electron microscopy.
Möller L; Schünadel L; Nitsche A; Schwebke I; Hanisch M; Laue M
Viruses; 2015 Feb; 7(2):666-79. PubMed ID: 25674771
[TBL] [Abstract][Full Text] [Related]
8. β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training.
Pilchová V; Prajeeth CK; Jendrny P; Twele F; Meller S; Pink I; Fathi A; Addo MM; Volk HA; Osterhaus A; von Köckritz-Blickwede M; Schulz C
J Virol Methods; 2023 Jul; 317():114733. PubMed ID: 37068591
[TBL] [Abstract][Full Text] [Related]
9. Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: The example of SARS-CoV-2 and monkeypox virus.
Quéromès G; Frobert E; Bouscambert-Duchamp M; Oblette A; Valette M; Billaud G; Escuret V; Lina B; Morfin F; Gaymard A
J Med Virol; 2023 Jan; 95(1):e28126. PubMed ID: 36089749
[TBL] [Abstract][Full Text] [Related]
10. Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2.
Davies K; Arnold U; Buczkowski H; Burton C; Welch SR; Green N; Strachan R; Beetar-King T; Spencer P; Hettiarachchi N; Hannah MJ; Jones M; Cane PA; Bruce CB; Woodford N; Roberts ADG; Killip MJ
Sci Rep; 2021 Dec; 11(1):23379. PubMed ID: 34862448
[TBL] [Abstract][Full Text] [Related]
11. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N
BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281
[TBL] [Abstract][Full Text] [Related]
12. Propagation, Inactivation, and Safety Testing of SARS-CoV-2.
Jureka AS; Silvas JA; Basler CF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32517266
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting stability and infectivity of SARS-CoV-2.
Chan KH; Sridhar S; Zhang RR; Chu H; Fung AY; Chan G; Chan JF; To KK; Hung IF; Cheng VC; Yuen KY
J Hosp Infect; 2020 Oct; 106(2):226-231. PubMed ID: 32652214
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of Influenza A virus, Adenovirus, and Cytomegalovirus with PAXgene tissue fixative and formalin.
Kap M; Arron GI; Loibner M; Hausleitner A; Siaulyte G; Zatloukal K; Murk JL; Riegman P
Biopreserv Biobank; 2013 Aug; 11(4):229-34. PubMed ID: 24845590
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of Coronaviruses during Sample Preparation for Proteomics Experiments.
Grossegesse M; Leupold P; Doellinger J; Schaade L; Nitsche A
J Proteome Res; 2021 Sep; 20(9):4598-4602. PubMed ID: 34432478
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the enveloped virus phi6 with hydrodynamic cavitation.
Zupanc M; Zevnik J; Filipić A; Gutierrez-Aguirre I; Ješelnik M; Košir T; Ortar J; Dular M; Petkovšek M
Ultrason Sonochem; 2023 May; 95():106400. PubMed ID: 37060711
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of foot-and-mouth disease virus A/IRN/8/2015 with commercially available lysis buffers.
Wood BA; Mioulet V; Henry E; Gray A; Azhar M; Thapa B; Diederich S; Hoffmann B; Beer M; King DP; Eschbaumer M
J Virol Methods; 2020 Apr; 278():113835. PubMed ID: 32035122
[TBL] [Abstract][Full Text] [Related]
18. Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model.
de Castro Barbosa E; de Souza Andrade A; Duarte MM; Faria G; de Melo Iani FC; Ataide ACZ; Cunha LM; Duarte CG; Fialho SL; Caldas S
Mol Immunol; 2022 Jul; 147():199-208. PubMed ID: 35644072
[TBL] [Abstract][Full Text] [Related]
19. Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads.
Pan Y; Long L; Zhang D; Yuan T; Cui S; Yang P; Wang Q; Ren S
Clin Chem; 2020 Jun; 66(6):794-801. PubMed ID: 32246822
[TBL] [Abstract][Full Text] [Related]
20. Stability of SARS-CoV-2 and other airborne viruses under different stress conditions.
Fumagalli MJ; Capato CF; de Castro-Jorge LA; de Souza WM; Arruda E; Figueiredo LTM
Arch Virol; 2022 Jan; 167(1):183-187. PubMed ID: 34727217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
